Somanetics to move Nasdaq listing

Somanetics (Troy, Michigan) said that Nasdaq has approved its application to move its listing from the Nas-daq Capital Market (formerly known as the Nasdaq SmallCap Market) to the Nasdaq National Market.

Somanetics' common shares began trading on the Nasdaq National Market on Feb. 7.

Somanetics makes the INVOS System, a non-invasive patient monitoring system that continuously measures changes in the blood oxygen levels in the brain.

Digirad certified for new ISO standard

Digirad (Poway, California), a provider of cardiovascular imaging services and solid-state nuclear medicine imaging products to physicians' offices, hospitals and imaging centers, said it has been awarded certification to the most recent International Standard Organization (ISO) standard for medical device manufacturer quality management system requirements, ISO 13485:2003.

Diasys not in compliance with Amex

DiaSys (Waterbury, Connecticut) reported that on Jan. 30, it received a letter from staff of the American Stock Exchange advising that the company was not in compliance with the Amex listing requirements in that it had shareholders' equity of less than $4 million and losses from continuing operations and/or net losses in three out of its four most recent fiscal years.

The staff letter indicated an intent to immediately initiate delisting proceedings.

The company does not believe that it will be able to meet such listing requirements during its current fiscal year, ending June 30, and has elected not to appeal the Amex staff determination. The company's common stock has been submitted for trading on the National Association of Securities Dealers bulletin board. The company intends to resign from the Amex at such time as the bulletin board listing is approved.

DiaSys makes medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide.

Aspect Medical to relocate headquarters

Aspect Medical Systems (Newton, Massachusetts), reported that it has entered into a lease agreement to relocate its corporate headquarters to 1 Upland Rd. in Norwood, Massachusetts, in late 2006.

Under the terms of the agreement, the company will occupy 100,000 square feet at the end of 2006 and will expand to 135,000 square feet by 2008. The Norwood facility more than doubles the capacity of Aspect's current facility.

"Aspect has experienced significant growth over the past two years as a result of the increased recognition of the quality and safety benefits that our brain monitoring technology provides for patients and healthcare providers," said CFO Mike Falvey.

"We expect this growth to continue in the coming years," he said. "The new Upland Road facility provides us with the ability to increase manufacturing capacity so that we can expand our product line and accommodate expected growth while providing a cost effective, high-quality and high-productivity work environment for our employees."

Under the terms of the agreement Aspect will lease the facility for 10 years, with additional rights to extend the lease.

Calypte Biomedical not in Amex compliance

Calypte Biomedical (Lake Oswego, Oregon) said that on Feb. 2, it received notice from the American Stock Exchange indicating that the company no longer complies with the exchange's continued listing standards set forth in the exchange's Company Guide. Specifically, the exchange noted that the company has shareholders' equity of less than $2 million and losses from continuing operations and/or net losses in two out of its three most recent fiscal years.

Amex said its financial condition has become so impaired that it appears questionable, in the opinion of the exchange, as to whether the company will be able to continue operations and/or meet its obligations as they mature. As a result of this lack of compliance, the exchange's staff has determined to initiate delisting proceedings with respect to the company's common stock.

Calypte has until Feb. 10 to request an appeal.

Calypte Biomedical is focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases.

No Comments